Cigna Aimovig Prior Authorization: Automating Approval Workflows

Navigating Cigna Aimovig prior authorization can be complex, involving distinct channels for medical and pharmacy benefits. Klivira streamlines this process, integrating with Cigna Healthcare and Evernorth systems to accelerate approvals for erenumab.

For revenue cycle directors and prior authorization coordinators, managing specialty drug approvals like Aimovig (erenumab) under Cigna's varying benefit structures demands precision. Understanding the specific submission pathways, utilization management criteria, and potential denial patterns is critical to minimizing delays and reducing administrative burden. Klivira's platform is designed to automate these intricate workflows.

Understanding Aimovig and Cigna's Coverage Landscape

Aimovig (erenumab) is a CGRP receptor antagonist indicated for the preventive treatment of chronic and episodic migraine. As a specialty medication, its coverage under Cigna Healthcare plans often involves specific prior authorization requirements, including step therapy through generic preventive therapies. These policies are designed to ensure medical necessity and appropriate utilization.

Prior Authorization Submission Channels for Aimovig

For Aimovig, prior authorization submissions typically route through Evernorth's Express Scripts, which manages Cigna's pharmacy benefit. Prescriber-initiated workflows can leverage established ePA partners like CoverMyMeds and Surescripts. In cases where Aimovig might fall under a medical benefit for administration, submissions would route through the CignaforHCP.com provider portal, which also accepts X12 278 transactions via clearinghouses.

Cigna's Utilization Management and Policy Application

Cigna Healthcare publishes detailed coverage policies and medical-necessity guidelines on its public provider site. For specialty drugs like Aimovig, these policies outline clinical indication requirements, step therapy protocols, and quantity limits. Klivira's platform integrates with these policy libraries, enabling proactive identification of criteria and automated documentation assembly to meet Cigna's specific requirements.

Expediting Aimovig PA: Turnaround Times and Electronic Pathways

Cigna's commercial PA timeframes are subject to state insurance regulations, while Medicare Advantage plans are impacted by CMS-0057-F, mandating 72-hour standard and 24-hour expedited PA timeframes. Express Scripts has long-established electronic PA capabilities through CoverMyMeds and Surescripts, facilitating rapid submission for pharmacy benefits. Klivira leverages these electronic channels to accelerate the prior authorization process.

Common Denial Reasons and Appeal Pathways for Aimovig with Cigna

Denials for Aimovig prior authorizations from Cigna Healthcare or Evernorth's Express Scripts often stem from insufficient documentation, failure to meet step therapy requirements, or medical necessity criteria not being met. Klivira's system helps mitigate these by ensuring complete submissions. Cigna provides clear appeal pathways, including peer-to-peer reviews for clinical denials, as documented on their provider portal and in the Cigna Provider Manual.

Klivira's Role in Streamlining Cigna Aimovig Prior Authorization

Klivira automates the entire Cigna Aimovig prior authorization workflow, from EMR data extraction to submission via CignaforHCP or Express Scripts' ePA partners. Our platform proactively identifies policy requirements, flags missing documentation, and tracks PA status, significantly reducing manual effort and improving approval rates for erenumab. This ensures your team can focus on patient care rather than administrative overhead.

Frequently asked questions

Which Cigna entity handles Aimovig prior authorizations?

For most Aimovig prescriptions, Evernorth's Express Scripts manages the pharmacy benefit prior authorization. If the drug were to be administered under a medical benefit, Cigna Healthcare would manage the PA through their CignaforHCP provider portal. It's crucial to distinguish between Cigna Healthcare (the plan provider) and Evernorth (the health services brand, including Express Scripts).

What are common reasons for Aimovig PA denials by Cigna?

Common denial reasons include insufficient documentation to support medical necessity, failure to demonstrate completion of required step therapy with other preventive migraine medications, or non-compliance with quantity limits outlined in Cigna's coverage policies. Ensuring all clinical criteria are met and thoroughly documented is key to avoiding delays.

How can I submit an electronic prior authorization for Aimovig to Cigna?

Electronic prior authorization (ePA) for Aimovig through Express Scripts can be submitted via industry-standard platforms like CoverMyMeds and Surescripts. These ePA channels facilitate direct submission from the prescriber's EMR or a web portal. Klivira integrates with these ePA systems to automate the submission process, ensuring efficiency and accuracy.

Are there specific turnaround times for Aimovig PAs with Cigna?

Yes, Cigna adheres to state-mandated minimums for commercial plans, which vary by jurisdiction. For Medicare Advantage plans, Cigna is subject to CMS-0057-F, requiring a 72-hour standard and 24-hour expedited review timeframe. Klivira's automation helps track these deadlines and prioritize urgent submissions.

What is the appeal process if Cigna denies an Aimovig prior authorization?

If an Aimovig PA is denied, Cigna's appeal process typically begins with an internal review. Providers can initiate a peer-to-peer review for clinical denials. The specific steps and required documentation for appeals are detailed on the CignaforHCP provider portal and in the Cigna Provider Manual, with distinct pathways for commercial and Medicare Advantage lines.